Explore Irazú Oncology’s leadership team, OMV platform, and development strategy. Contact us to learn more about the company, strategic collaborations, and potential investment opportunities.
Company Overview
Founded in 2022, Irazú Oncology is developing next-generation cancer immunotherapies using its proprietary Outer Membrane Vesicles (OMV) platform. The company’s technology harnesses engineered bacterial nanoparticles to deliver cancer antigens, potentially enabling more effective and accessible treatment options for cancer patients. Irazú combines scientific innovation with efficient manufacturing to advance its pipeline of cancer immunotherapies.
Investor Contact
Jeff Strovel, PhD
Chief Executive Officer
Irazú Oncology
jstrovel@irazuoncology.com
Note: This page and the materials contained herein are provided for informational purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any securities. Any investment opportunities, if available, will be offered only to qualified investors pursuant to applicable securities laws.
Irazu Oncology Contact Form
Fill out my online form.
Contact Us
Irazu Oncology, LLC
bcawthern@irazuoncology.com
(443) 838-3002
4 N. Martin Luther King Jr. Blvd
Suite O-11
Baltimore, MD 21201